First-quarter results of Sartorius Stedim Biotech : vimarsan

First-quarter results of Sartorius Stedim Biotech


Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent
A good 23 percentage points of growth contributed by the coronavirus pandemic
Accelerated expansion of production capacities in all regions on track as planned
Sartorius Stedim Biotech, a leading partner of the biopharma industry, had an exceptionally strong start to fiscal 2021 and grew substantially in order intake
1, sales revenue and earnings. This was fueled by strong fundamental growth, additional business from vaccine manufacturers, and acquisitions. 
"Many of our products play an essential role in helping to overcome the pandemic. In addition to a very positive general business performance in the first quarter, we accordingly experienced strong demand for our products and technologies used in the production of vaccines and achieved a sharp increase in sales. The substantial rise in the company's profit margin was also supported by underproportionate development of costs, such as the low number of business trips as well as fewer new hires in non-production areas. These effects are expected to decrease as the year progresses. In many areas, we are working at the limits of our capacity and are therefore continuing to move ahead with accelerating the expansion of our production facilities and are hiring additional employees," said Joachim Kreuzburg, Chairman of the Board of Directors and CEO. In the first three months of the current year, Sartorius Stedim Biotech has already created some 600 new jobs; the Group now employs around 8,200 people in total.

Related Keywords

China , Germany , Puerto Rico , United States , South Korea , Aubagne , Provence Alpes Côd Azur , France , America , French , Petra Kirchhoff , Joachim Kreuzburg , Asia Pacific , Watersep Bioseparations , Linkedin , Head Of Corporate Communications Investor Relations , Sartorius Stedim Biotech Group , Danaher Corporation , Stedim Biotech , Sartorius Stedim Biotech , Middle East , European Summer Time , Performance Indicators , First Quarter , Biological Industries , North America , Corporate Communications , Investor Relations , Sartorius Stedim Biotech Sa , சீனா , ஜெர்மனி , ப்வெர்டோ ரிக்கோ , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கொரியா , பிரான்ஸ் , அமெரிக்கா , பிரஞ்சு , பெட்ரா கர்க்‌ஹாஃப் , ஆசியா பெஸிஃபிக் , சென்டர் , தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , ட்யாநேஹர் நிறுவனம் , நடுத்தர கிழக்கு , ஐரோப்பிய கோடை நேரம் , முதல் காலாண்டு , உயிரியல் தொழில்கள் , வடக்கு அமெரிக்கா , பெருநிறுவன தகவல்தொடர்புகள் , முதலீட்டாளர் உறவுகள் ,

© 2025 Vimarsana